[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]

Aktuelle Urol. 2011 Jul;42(4):242-6. doi: 10.1055/s-0031-1271548. Epub 2011 Jun 30.
[Article in German]

Abstract

With the introduction of targeted drug therapies, a paradigm shift for the treatment of metastatic renal cell carcinoma has taken place. New compounds like sunitinib, sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards to replace the use of cytokines as standard therapy. Recently, these substances have been complemented by everolimus and pazopanib. An interdisciplinary consensus conference was held to discuss which criteria to consider when using these drugs (treatment sequence) and what questions remain unanswered based on the current study situation (open questions). Results from the 2009 conference provided the basis for the 2010 meeting. The results of the 2010 conference are presented as short theses.

Publication types

  • Consensus Development Conference

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / therapeutic use
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / genetics*
  • Carcinoma, Renal Cell / mortality
  • Carcinoma, Renal Cell / surgery
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • Cooperative Behavior*
  • Cytokines / adverse effects
  • Cytokines / therapeutic use
  • Disease Progression
  • Everolimus
  • Evidence-Based Medicine
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Interdisciplinary Communication*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / surgery
  • Molecular Targeted Therapy / methods*
  • Niacinamide / analogs & derivatives
  • Patient Care Team*
  • Phenylurea Compounds
  • Platelet-Derived Growth Factor / antagonists & inhibitors
  • Platelet-Derived Growth Factor / genetics
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use
  • Pyrroles / adverse effects
  • Pyrroles / therapeutic use
  • Randomized Controlled Trials as Topic
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Sorafenib
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Sunitinib
  • Survival Rate
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / genetics
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzenesulfonates
  • Cytokines
  • Indoles
  • Phenylurea Compounds
  • Platelet-Derived Growth Factor
  • Pyridines
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • temsirolimus
  • pazopanib
  • Everolimus
  • Sorafenib
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sunitinib
  • Sirolimus